RIPR-PD-1

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRIPR-PD-1
Drug Alias NameRIPR-PD-1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnti-CD45Anti-PD-1
TargetsLeukocyte common antigenProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesStanford University
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A